Imaging in the Management of Ischemic Cardiomyopathy Special Focus on Magnetic Resonance by Schuster, Andreas et al.
Journal of the American College of Cardiology Vol. 59, No. 4, 2012
© 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00STATE-OF-THE-ART PAPER
Imaging in the Management of Ischemic Cardiomyopathy
Special Focus on Magnetic Resonance
Andreas Schuster, MD,* Geraint Morton, MA, MBBS,* Amedeo Chiribiri, MD, PHD,*
Divaka Perera, MD,* Jean-Louis Vanoverschelde, MD, PHD,† Eike Nagel, MD, PHD*
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Heart failure of ischemic origin has become increasingly common over the last decade because of the improved
survival of patients with acute myocardial infarction. Revascularization with coronary bypass grafting or percuta-
neous coronary intervention plays a pivotal role in patients with ischemic cardiomyopathy, although these inter-
ventions are often associated with relatively high peri-procedural risk. The pathophysiological substrate of isch-
emic cardiomyopathy is heterogeneous, varying from predominantly hibernating myocardium to irreversible
scarring. There is evidence to suggest that patients with hibernating myocardium benefit most from revascular-
ization, whereas medical therapy is associated with an adverse prognosis. Therefore, noninvasive testing is rec-
ommended by relevant guidelines to guide optimal management in these patients. However, the role of noninva-
sive testing has recently been challenged. There are various imaging modalities available that provide
information on different aspects of the disease, and therefore, they differ significantly in sensitivity and specific-
ity. In clinical practice, choosing among the different imaging modalities can be difficult. Cardiac magnetic reso-
nance has evolved into a comprehensive modality that can accurately determine the amount of hibernating
myocardium as well as the presence and degree of myocardial ischemia and the extent of the scar. This paper
reviews the indications, accuracy, and clinical utility of the available imaging techniques, with a special focus on
cardiac magnetic resonance in ischemic cardiomyopathy, and provides an outlook on how this field might evolve
in the future. (J Am Coll Cardiol 2012;59:359–70) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.08.076Heart failure and myocardial infarction secondary to coro-
nary artery disease (CAD) constitute leading causes of death
(1). Despite recent advances in therapy, ischemic cardiomy-
opathy (ICM) is associated with high mortality, and deter-
mining the best management is challenging. In patients
with normal ejection fraction (EF), prognosis in CAD is
associated with the ischemic burden and the amount of
ischemia reduction achieved by therapy (2), as well as the
presence or absence of hibernating myocardium (2,3). How-
ever, the former has not been specifically shown for patients
with reduced EF.
The definition of ICM is inconsistent. Some trials,
including the STICH (Surgical Treatment for Ischemic
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accepted August 2, 2011.Heart Failure) trial, defined it as a severe reduction of left
ventricular (LV) function (35%) (4,5), whereas others use
an LV function 50% in the presence of severe CAD (3,6).
For this review, we use the latter definition. The pathophys-
iological substrate of ICM is heterogeneous, varying from
predominantly hibernating myocardium to irreversible scar-
ring. The concept of “hibernating myocardium” refers to
myocardium that is supplied by a diseased coronary artery
and is ischemic and dysfunctional but remains alive and thus
has the potential to regain contractility after revasculariza-
tion. There are different definitions of hibernating myocar-
dium. The most accepted definition is an improvement in
contractility after revascularization. Even though this defi-
nition is the most accurate, it is only after revascularization
that the diagnosis can be made (i.e., it is a retrospective
definition [7,8] and thus not useful for clinical decision
making). Therefore, all diagnostic tests use surrogate defi-
nitions to assess the presence of hibernating myocardium.
These definitions vary, and different imaging techniques
provide information on different aspects of the pathophys-
iology such as metabolic imaging, scar imaging, or contrac-
tile reserve. Consequently, the results may depend on the
chosen imaging test.
Even though there is less evidence, the importance of an
additional ischemic component to the presence of hibernat-
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creasingly recognized (9). Be-
cause the relative importance of
the ischemic component has not
been fully established and differ-
ent imaging strategies yield dif-
ferent results, it remains difficult
to decide which test is clinically
most suitable and which param-
eter most important in a given
patient.
Hibernating Myocardium
The observation of dysfunctional
myocardium regaining function af-
ter coronary artery bypass grafting
(CABG) (10) led to the introduc-
tion of “hibernation” (11) and was
related to reduced coronary blood
flow (12).
Hibernating myocardium re-
fers to a progressive and dynamic
condition of chronic abnormally
contracting myocardium, with
function that improves after re-
vascularization. The exact patho-
physiology is still controversial.
Dysfunction initially is probably
caused by reduced flow reserve
leading to ischemic episodes during stress (13). Myocardial
ischemia rapidly impairs contractile function, which may
persist for several hours after reperfusion (myocardial stun-
ning), and its repetitive occurrence might lead to chronic
dysfunction even when perfusion at rest is still normal (14).
This is referred to as “perfusion-contraction mismatch.” Over
time, perfusion at rest will decrease, leading to a restitution of
perfusion-contraction matching (15). In parallel with this,
increased fibrosis and myocyte alterations (degeneration and
apoptosis) occur, reducing the likelihood of complete func-
tional recovery after revascularization (Fig. 1).
Patients with hibernating myocardium (by any diagnostic
test) have been shown to have a significant survival advan-
tage following revascularization compared with those re-
ceiving medical therapy alone. Allman et al. (3) presented a
meta-analysis pooling the data of 3,088 patients from 24
studies between 1992 and 1999. Hibernating myocardium
was determined using single-photon emission computed
tomography (SPECT), positron emission tomography
(PET), or dobutamine stress echocardiography (DSE) with
a 2-year follow-up. A strong association was found between
hibernating myocardium identified with noninvasive testing
and improved survival after revascularization. Revasculariza-
tion was associated with a nearly 80% reduction in mortality
in patients with hibernating myocardium (16% with medical
Abbreviations
and Acronyms
CABG  coronary artery
bypass grafting
CAD  coronary artery
disease
CMR  cardiac magnetic
resonance
CT  computer tomography
DSE  dobutamine stress
echocardiography
DSMR  dobutamine
stress magnetic resonance
EF  ejection fraction
FFR  fractional flow
reserve
ICM  ischemic
cardiomyopathy
LGE  late gadolinium
enhancement
LV  left ventricular
MCE  myocardial contrast
echocardiography
PET  positron emission
tomography
SPECT  single-photon
emission computed
tomographytherapy vs. 3.2% with revascularization). Conversely, in theabsence of hibernating myocardium, there was no difference
in mortality with revascularization (7.7%) versus medical
therapy (6.2%).
Camici et al. (16) more recently pooled the data from 14
nonrandomized studies, published between 1998 and 2006,
that reported long-term Kaplan-Meier survival curves. They
also found a survival benefit associated with revasculariza-
tion compared with medical treatment in patients with
hibernating myocardium but no benefit in those without.
Interestingly, and in apparent contradiction to Allman et al.
(3), the annual mortality rate in patients treated medically
appeared to be independent of the presence of hibernating
myocardium. Whether this contradiction might be ex-
plained by optimized patient care due to improved medical
therapy including implantable cardioverter defibrillators or a
higher revascularization rate in patients with significant
amounts of hibernating myocardium remains speculative.
The main disadvantage of both studies is their retrospective
nature and the lack of randomization.
The long-awaited STICH trial is a prospective, random-
ized, multicenter outcome study comparing 1,212 patients
with ICM (EF 35%) assigned to intensive medical ther-
apy with patients assigned to intensive medical therapy and
CABG (4). There was no significant difference with respect
to the primary endpoint of death from any cause (4).
A prospective substudy in 601 patients investigated whether
assessment of hibernating myocardium (with SPECT and/or
DSE) can identify patients who would benefit most from
revascularization (5). A total of 298 patients were assigned to
intensive medical therapy and CABG, and 303 were assigned
to receive intensive medical therapy alone. Thirty-seven per-
cent of patients with hibernating myocardium and 51% of
patients without hibernating myocardium died during follow-
up. After adjustment for differences in baseline variables and
risk factors, there was no significant association of hibernating
myocardium with mortality. Furthermore, patients with hiber-
nating myocardium who were assigned to CABG plus medical
therapy did not have improved survival compared with those
assigned to medical therapy alone. Unfortunately, several lim-
itations of this trial must be considered. 1) Assessment of
hibernating myocardium was performed only in those STICH
patients when investigators had the test available and actively
referred the patient. It is unclear whether this referral was
random or related to clinical factors. 2) There was an imbal-
ance between patient groups because 81% of all patients had
significant hibernating myocardium (leaving 19% without hi-
bernating myocardium). 3) To be classified as a patient having
significant hibernating myocardium, 65% of the myocardium
had to be hibernating with SPECT (11 segments) or 31% of
the myocardium had to be hibernating with DSE (5 seg-
ments). In addition, hibernating territories were not related to
the coronary anatomy. Both factors may compound interpre-
tation of these findings. 4) Hibernating myocardium was
assessed with SPECT or DSE, neither of which is considered
to be the gold standard tool for this investigation. In contrast,
the retrospective analyses that demonstrated improved survival
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magnetic resonance (CMR) (16). 5) Patients in the medical
therapy arm of the trial had a significantly higher rate of aspirin
and statin use at baseline compared with patients who under-
went CABG, which may have improved survival in the
medical therapy group.
Current guidelines recommend noninvasive testing be-
fore revascularization (17). This may be subject to change
based on the STICH trial. However, there is still a need for
well-defined prospective outcome studies using state-of-
the-art noninvasive testing to plan revascularization in
patients with ICM.
Ischemia
The role of inducible ischemia in ICM is less well estab-
lished than the role of hibernating myocardium.
In patients with stable, symptomatic CAD and preserved
EF, revascularization only confers a prognostic benefit
(reduced rate of death, nonfatal myocardial infarction, and
repeat revascularization) if patients have significant myocar-
dial ischemia (as assessed by fractional flow reserve [FFR]),
whereas revascularization of stenoses not limiting flow has a
negative effect on prognosis. The role of “medical therapy
only,” however, was not clarified in this study (18). Vaso-
Figure 1 Development of Ischemic Cardiomyopathy as a Time-D
At a pathophysiological level, there are 3 different phenomena contributing: 1) init
contractile function; 2) over time, there will eventually be a decrease in resting pe
state of hibernating myocardium; and 3) there is further disease progression with
of functional recovery following revascularization diminishes as the disease progre
no recovery later (late second to third stage).dilator stress CMR correlates well with FFR (19) and can be dused as a noninvasive alternative to FFR in similar patients
to identify individuals at high risk for cardiac death, nonfatal
myocardial infarction, or congestive heart failure (20).
It is unknown whether this holds true in patients with
ICM with or without hibernating myocardium. Rizzello et
al. (9) examined 128 consecutive patients with DSE before
revascularization and showed that the presence of ischemia
did not add significantly to predicting outcome, whereas the
extent of hibernating myocardium was a strong predictor of
long-term prognosis. In contrast, Pasquet et al. (21) re-
ported that ischemia as determined by 201thallium-SPECT
as an important predictor of outcome in patients with
hronic left ventricular dysfunction. They prospectively
ssessed hibernating myocardium and ischemia in 137
onsecutive patients who underwent 201thallium-SPECT
and DSE with a follow-up of 3 years and reconfirmed the
prognostic value of revascularization in patients with hiber-
nating myocardium. In addition, they found improved
survival in patients with ischemic myocardium (as deter-
mined by 201thallium-SPECT) who underwent revascular-
zation independent of the presence of hibernating myocar-
ium (21). Interestingly and in line with Rizzello et al. (9),
hey did not show a relationship between ischemia assessed
y high-dose DSE and prognosis. It is unclear whether this
dent Phenomenon
petitive episodes of stunning result in a mismatch between oxygen delivery and
(oxygen delivery), restoring the perfusion/contraction balance and leading to the
s and myocyte alterations marking the end stage of the disease. The likelihood
with a high likelihood of recovery early (first to early second stages) and little toepen
ially re
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fibrosi
sses,ifference can be explained by the different pathophysiolo-
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whereas 201thallium-SPECT reflects cellular integrity com-
bined with flow) or possible technical limitations of DSE,
which might suffer from poor acoustic windows and
difficult endocardial border delineation, especially in
patients with ICM. The findings also need to be inter-
preted in the context of the relatively small study popu-
lation and the unblinded, nonrandomized study design. It
remains unclear to date whether ischemia is an important
parameter in patients with ICM. Given the controversial
results of the STICH trial and the lack of data on
ischemia testing in ICM, there is a clear need for
prospective outcome studies investigating the relative
importance of both ischemia and hibernating myocar-
dium, preferably in a multicenter setting.
Surrogate Measures of Hibernating MyocardiumTable 1 Surrogate Measures of Hibernating Myocardium
Modalities and Targets Metabolism Perfu
CMR  
CT  
Echocardiography  
PET  
SPECT  
Assessment of functional integrity
of myocardial cells
Detection of blo
the myocard
CMR cardiacmagnetic resonance; CT computed tomography; PET positron emission tomogr
his assessment.
Characteristics of Hibernating MyocardiumTable 2 Characteristics of Hibernating Myocardium
Imaging Technique Imaging Target
Echocardiography Contractile reserve (dobutamine stress echocardiograph
Perfusion (MCE)
Scarring (MCE)
SPECT Contractile reserve (dobutamine-gated SPECT)
Perfusion intact cell membrane (201thallium-SPECT)
Perfusion intact cell membrane/intact mitochondria
(99mtechnetium-tetrofosmin/MIBI SPECT)
Free fatty acid metabolism (123I-BMIPP SPECT)
Glucose metabolism (18FDG-SPECT)
PET Perfusion (13NH3-labeled ammonia,
15O2-labeled water,
and 82Rb-labeled PET) (71)
Glucose metabolism (FDG-PET)
CMR Perfusion (perfusion CMR)
Oxygenation (high-dose DSMR)
Contractile reserve (low-dose DSMR)
Scarring (LGE-CMR)
Oxygenation (blood oxygen level–dependent CMR)
CT Perfusion
Scarring (DE-CT)
Integrated PET-CT and
SPECT-CT
Combined DE-CT and perfusion PET (13NH3 and
15O2 PE
*Myocardium at risk for significant ischemia.
BMIPP  -methyl-p-iodophenyl-pentadecanoic acid; DE  delayed enhancement; DSMR  dobutami
CE  myocardial contrast echocardiography; MIBI  methoxyisobutylisonitrile; other abbreviations as iClinically, a single test that provides assessment of the
presence and extent of hibernating myocardium and the
presence and severity of ischemia seems most appropriate to
guide therapy. The current evidence is, however, not ade-
quate to direct clinicians toward either an ideal diagnostic
test or toward understanding the relative importance of
ischemia versus hibernating myocardium in patients with
ICM (22).
LV Function
Impaired LV function is associated with adverse prognosis
(23). The potential survival benefit in patients with hiber-
nating myocardium who undergo revascularization may well
be mostly explained by improved global LV function after
restoration of blood flow. Bax et al. (24) pooled data from
Nonviability Scar Contractile Reserve
 
 
() 
 
 ()
w toward Exact localization and size of
necrosis/fibrosis
Assessment of contractile function
PECT single-photon emission computed tomography; () technique potentially useful to make
Definition of Hibernating Myocardium
Improvement in contraction (visual or quantitative analysis using strain rate [69])
Homogenous contrast enhancement during rest steady-state perfusion (35)
Contrast agent uptake visualized with 3-dimensional echocardiography (36)
Improvement in contraction (70)
Tracer uptake 50%
Tracer uptake 65%
Preserved glucose metabolism
Irreversible injury: flow metabolism match; ischemic but viable:
flow metabolism mismatch
Irreversible injury: defect with stress and at rest;
Myocardium at risk*: inducible defect with stress and not at rest
New wall motion abnormalities with stress reflect cellular hypoxia
Improvement in function
Gadolinium uptake visualized in LGE images
Irreversible injury: defect with stress and at rest;
Myocardium at risk*: inducible defect with stress and not at rest
Irreversible injury: defect with stress and at rest;
Myocardium at risk*: inducible defect with stress and not at rest
Iodine contrast agent uptake visualized in late enhancement images
Anatomy of coronary arteries, ischemia, and hibernating myocardiumsion
od flo
iumy)
T)ne stress magnetic resonance; FDG  fluorodeoxyglucose; LGE  late gadolinium enhancement;
n Table 1.
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201Thallium–single-photon emission computed tomography (SPECT) depends on intact cellular membranes and energy-dependent uptake via the NaK-antiporter. Technetium-
labeled tracers tetrofosmin (TF) and methoxyisobutylisonitrile (MIBI) are lipophilic cations that can be imaged with SPECT after passively crossing the mitochondrial membranes
(driven by the transmembrane electrochemical gradient), where they are retained. Dobutamine targets 1 and 2 adrenoreceptors (-AR), leading to increased intracellular Ca2
and positive inotropy. Responses to dobutamine stress are mainly imaged with dobutamine stress echocardiography and dobutamine stress magnetic resonance. 18-fluorode-
oxyglucose (18FDG) targets glucose metabolism and is mainly imaged with positron emission tomography (PET) after uptake via the glucose transporter uniporter. FDG is intra-
cellularly phosphorylated by hexokinase to FDG-6-phosphate, which is not further used in glycolysis or glycogen synthesis. 82-Rubidium (82Rb)-PET depends on intact cellular
membranes and energy-dependent uptake via the Na-K-antiporter similarly to 201thallium. 13NH3-PET depends on passive diffusion or on the active Na
-K-antiporter mecha-
nism. H2
15O diffuses freely through the membrane and reaches equilibrium between extravascular and intravascular compartments. Gadolinium is an extracellular contrast
agent that passively diffuses into the extracellular space. When the extracellular space is significantly increased (e.g., after cell membrane rupture in acute myocardial infarction
or in collagenous subendocardial scar as shown in this case), gadolinium accumulates and is retained due to altered wash in/wash out kinetics and can then be imaged with
late gadolinium enhancement–cardiac magnetic resonance imaging.Figure 3 Diagnostic Accuracy of Different Techniques to Assess Hibernating Myocardium
Although an increase in global ejection fraction (EF) after revascularization is associated with improved prognosis in patients with ICM, most studies have evaluated the
impact of revascularization on improvement of regional function of hibernating myocardium rather than global improvement of function. The black line represents late
gadolinium enhancement–cardiac magnetic resonance (LGE-CMR) as a reference standard for nonviability. The individual percentage terms refer to the extent of trans-
murality of scar. Although techniques addressing hibernating myocardium by looking at cellular integrity lie on or close to the LGE accuracy line (16,74), techniques look-
ing at contractile reserve reach a higher accuracy (16,48), which can be even further increased by applying quantitative wall motion analysis techniques such as strain
(51,75). DSE  dobutamine stress echocardiography; DSMR  dobutamine stress magnetic resonance; other abbreviations as in Figures 1 and 2.
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regional or global recovery. An improvement in global EF
was detected in 28 studies. In the presence of hibernating
myocardium, LVEF improved (from 37% to 45%), whereas
in the absence of hibernating myocardium, EF remained
unchanged (36%). Patients with an improvement in LVEF
after revascularization have an improved prognosis (25).
When considering revascularization, it is important to note
that even if regional wall motion remains unchanged, global
function may improve (26).
Noninvasive Functional Assessment
There are several imaging modalities assessing 3 main surro-
gate parameters of hibernating myocardium (Tables 1 and 2,
Positron Emission TomographyTable 3 Positron Emission Tomography
Target Tracer
Perfusion Perfusion tracer (15O2,
13NH3,
82Rb) Detection of b
competent
Hibernating myocardium Metabolism tracer FDG
(used in combination with
perfusion tracer 13NH3)
Metabolism: F
by hexokin
which is no
glycogen sy
Abbreviation as in Table 2.
Single-Photon Emission Computed TomographyTable 4 Single-Photon Emission Computed Tomography
Tracer Biological Properties
201Thallium Similar to potassium
(monovalent cation)
1. Initial tra
perfusion
2. Sustained
3–4 h af
cell mem
reflects h
99Technetium metastable
tetrofosmin and MIBI
Lipophilic cations Similar flow
higher en
compare
less radi
123I-BMIPP Radioiodine-labeled fatty acid tracer Metabolic im
persisten
increase
triglyceri
18FDG* Glucose analogue positron emitter Metabolic im
*With the introduction of 511 keV collimators, 18FDG is being increasingly used for SPECT imaging
DG is originally a PET tracer.
CAD  coronary artery disease; other abbreviations as in Tables 1 and 2.Fig. 2) (27): 1) myocardial metabolism with functional
integrity of cells and mitochondria; 2) nonviable tissue by
determining the localization and extent of necrosis or
fibrosis; and 3) contractile reserve during inotropic stimu-
lation. Different imaging modalities measure different as-
pects of physiology and pathophysiology, resulting in dif-
ferent accuracies (Fig. 3).
PET and SPECT. PET imaging is well validated, and
metabolism-perfusion mismatch has high negative and pos-
itive predictive values (Table 3) (28). With PET, myocardial
perfusion and metabolism can be fully quantified, a poten-
tial advantage compared with SPECT or DSE. Further-
more, PET is associated with outcome: A post hoc analysis,
PARR-2 (PET and Recovery Following Revascularization-2),
Kinetics Protocols
ow through
ls
1. Rest perfusion: first bolus injection
2. Stress perfusion: acquisition 5 half-times after
rest scan after second injection during
vasodilator stress
intracellularly phosphorylated
FDG-6-phosphate,
er used in glycolysis or
is
1. Rest perfusion
2. Metabolic imaging
Kinetics Protocols
ake dependent on regional
e (usually imaged
ction) dependent on
integrity, which
ting myocardium (72)
1. Stress: reversible defect from peak stress to
delayed “redistribution” (3–4 h or 24 h after
injection) is marker of reversible ischemia in
hibernating myocardium
2. Rest: reversible defect at redistribution indicates
hibernating myocardium with resting
hypoperfusion; fixed defects reflect scar tissue
3. Reinjection: in case of limited initial uptake during
stress in severe CAD, a “fixed” defect might be
present in hibernating myocardium because
201Tl is normally cleared from blood pool rapidly;
second “reinjection” of small dose of 201Tl at rest
is necessary to proof hibernating myocardium
after the redistribution images
cs but emission of
nd shorter half-life
201Tl (better detection and
Retention in mitochondria with minimal
redistribution requires separate injection at rest
and stress; information about perfusion and
hibernating myocardium; dysfunctional segments
with tracer uptake 65% are considered
hibernating
related to
ase in -oxidation with
t retention of BMIPP in
l
Assessment of hibernating myocardium and
“ischemic memory”; after ischemic episode,
fatty acid metabolism may be suppressed for
prolonged time, and BMIPP imaging can
demonstrate regional metabolic defect even if
perfusion has returned to normal
of glycolysis Hibernating myocardium shows preserved or even
relatively higher glucose metabolism compared
with flow; principle referred to as metabolism-
perfusion mismatch
al data have shown excellent agreement between SPECT and PET for FDG imaging (73); however,lood fl
vesse
DG is
ase to
t furth
nthescer upt
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with ICM and a myocardial perfusion-metabolism mis-
match of 7% and did not in those with 7% (29).
SPECT has been a cornerstone of noninvasive imaging
for many years. Myocardial perfusion and hibernating
myocardium can be assessed from tracer uptake and
redistribution specifically targeting cell membrane integ-
rity and mitochondrial function (Table 4, Fig. 2). Other
tracers targeting -oxidation and assessment of function
ith low-dose dobutamine are available, but their clinical
tility has not been sufficiently established (Table 4) (30).
he main disadvantages of PET and SPECT remain
heir radiation exposure and relatively low spatial resolution.
chocardiography. Echocardiography is widely avail-
ble, fast, relatively cheap, and therefore frequently used
rst line. Although improved function with low-dose
obutamine indicates hibernating myocardium (31,32),
he occurrence of new wall motion abnormalities at
igher stress levels or a biphasic response are considered
iagnostic of inducible myocardial ischemia. Myocardial
ontrast echocardiography (MCE) further improves the
ccuracy to detect regional wall motion abnormalities
33). MCE has also been proposed for the detection of
nducible myocardial ischemia during vasodilator stress
nd might evolve as an alternative to DSE for the
ssessment of ischemia (Table 5) (34,35). Quantification
f myocardial blood flow using MCE is accurate for the
EchocardiographyTable 5 Echocardiography
Modality Target
MCE Perfusion, hibernating myocardium
(microcellular integrity), and scar
Destruction (b
ultrasound
velocity of
microbubb
Scar imaging (MCE) Scar Contrast agen
with 3-dime
DSE Biphasic response: contractile
reserve and ischemia
Acquisition of
and variou
DSE  dobutamine stress echocardiography; MCE  myocardial contrast echocardiography; othe
Cardiovascular Magnetic ResonanceTable 6 Cardiovascular Magnetic Resonance
Target Method
Oxygenation DSMR (dobutamine  atropine) Increasing dosa
to achieve ta
Perfusion Vasodilator (adenosine, dipyridamole) Gadolinium first
Hibernating myocardium DSMR (dobutamine) Low dosages (
Hibernating myocardium Scar (LGE) Nonviability, extAbbreviations as in Tables 1 and 2.rediction of hibernating myocardium and seems to be
uperior to DSE and 201thallium-SPECT (32).
Echocardiography has also been used for the detection
nd quantification of myocardial infarct scars, and good
greement with late gadolinium enhancement (LGE)
MR has been demonstrated (36). However, these recent
dvances need to be confirmed in larger studies. Clini-
ally, routine echocardiography frequently suffers from
oor acoustic windows and inadequate endocardial bor-
er definition.
omputed tomography. Even though computed tomogra-
hy (CT) can be used to assess LV function (37), perfusion
38), and scar (Table 2) (39), its main clinical application is
maging of the coronary arteries. Especially in patients with
hronic CAD, CT may be limited by high calcium burden.
edicated cardiac PET-CT and SPECT-CT systems may
llow for the assessment of coronary artery anatomy and the
resence and extent of ischemia and hibernating myocardium
t the same time. Again, this approach might be hampered by
igh doses of ionizing radiation, particularly if coronary anat-
my, function, hibernating myocardium, and perfusion are
tudied (40).
ardiac magnetic resonance. CMR is a comprehensive,
ccurate, and increasingly available method to assess pa-
ients with ICM and to guide therapy (41). CMR is the
eference standard for the assessment of ventricular
olume and function and the visualization of scar. It is
hnique Protocols
h mechanical index
) and restoration
inuously infused
rast agent
1. Stress: replenishment of ultrasound beam after
microbubble destruction takes approximately 1 s
2. Rest: replenishment of ultrasound beam after
microbubble destruction takes approximately 5 s
3. Scar imaging: increased subendocardial or
transmural brightness
mulation visualized
l echocardiography (36)
Absence of scar in areas where there is hypokinesia
at rest diagnostic of hibernating myocardium
onal images at rest
s levels
1. Contractile reserve: low dosages of dobutamine
(5 to 10 g·kg1·min1)
2. ischemia: 40 g·kg1·min1 plus atropine to
meet target heart rate
viation as in Tables 1 and 2.
Protocols Interpretation
40 g·kg1·min1  atropine)
art rate ([220  age]  0.85)
Ischemia can be diagnosed in presence of new
wall motion abnormalities on cine CMR
perfusion Induced underperfusion (“perfusion defect”) with
stress that is reversible at rest is diagnostic
of inducible ischemia
·kg1·min1) Increased contractility at low-dose stress in
areas where there is hypokinesia at rest is
diagnostic of hibernating myocardium
fibrosis/necrosis Absence of scar in areas where there is
hypokinesia at rest is diagnostic of
hibernating myocardiumTec
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Noninvasive Imaging in Ischemic Cardiomyopathy January 24, 2012:359–70highly accurate to assess contractile reserve and ischemia
in a single examination without exposure to ionizing
radiation. Furthermore, recent registry data showed that
CMR provides an unsuspected new diagnosis in every
fifth referral (42).
The main limitations at this time are the exclusion of
patients with pacemakers or cardiac resynchronization ther-
apy devices and the potential reduction of image quality in
patients with significant arrhythmia or severe shortness of
Figure 4 CMR Scanning Following a Standardized Protocol Rec
The figure shows the different protocols (43) we currently use to assess patients
our standard protocol if the clinical question is mainly hibernating myocardium. If
or high-dose dobutamine (protocol 3). Although a high-dose dobutamine protocol is
what higher because of fewer complications. It is important to note that there is c
dobutamine stress in patients with low EF. DSMR  dobutamine stress magnetic
SCMR  Society for Cardiovascular Magnetic Resonance; SSFP  steady-state frebreath.CMR of Hibernating Myocardium
Prediction of functional recovery. A basic CMR protocol
includes the assessment of LV volumes and global and
regional function (43) based on contiguous short-axis cine
images (44). Different protocols focused on the clinical
question are shown in Figure 4. LGE imaging visualizes
irreversible damage (myocardial scar or fibrosis) due to an
accumulation of contrast agent in areas with increased
ended by the SCMR
M. Protocol 1 is a basic protocol for ejection fraction (EF) and scar. Protocol 2 is
ia is also of clinical relevance, we add adenosine stress perfusion (protocol 4)
tly quicker, the feasibility of adenosine perfusion in patients with low EF is some-
y no evidence showing the efficacy of adenosine perfusion imaging or high-dose
nce; HD  high dose; LAX  long axis; LD  low dose; SAX  short axis;
ession; other abbreviations as in Figure 1.omm
with IC
ischem
sligh
urrentl
resona
e precextracellular space (Fig. 2) (45). In LGE images, viable
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January 24, 2012:359–70 Noninvasive Imaging in Ischemic Cardiomyopathymyocardium appears dark, whereas necrotic or fibrotic
myocardial tissue appears bright. Myocardium with wall
motion abnormalities at rest but remaining viable tissue is
then regarded as hibernating.
LGE has unprecedented spatial resolution (46) and can
determine the transmural extent of scar and the remaining
viable rim, which is not possible with other imaging
modalities. The likelihood of functional recovery can be
predicted based on scar transmurality (45): in the absence of
scar, the likelihood of functional recovery is 78%; if the scar
has more than 75% transmural extent, the likelihood of
recovery is 2%. However, the value of LGE to predict
functional recovery in intermediate scars (ranging from 1%
to 75% transmurality) is limited, with a likelihood of
Figure 5 Images of a 51-Year-Old Male Patient
With RCA-CTO
CMR showed reduced left ventricular (LV) systolic function (LVEF 45%) at rest
with akinesia of the inferolateral wall at basal level. There was nontransmural
scarring (25% to 50%) in the region of the wall motion abnormality. There was
extensive inducible ischemia in the inferior and inferolateral walls with adeno-
sine stress, which was not present at rest. The wall motion abnormality in the
inferolateral wall at basal level was completely reversible with normal wall
thickening during LD-DSMR (arrowheads). RCA-CTO  right coronary artery
chronic total occlusion; other abbreviations as in Figures 3 and 4.approximately 40% (45). In these patients, additional low-dose dobutamine stimulation can be performed in the same
examination. Forty-two percent of segments with an
intermediate scar show contractile reserve during low-
dose dobutamine stimulation (47), and the combination
of contractile reserve and scar quantification leads to
optimal results (48).
The specificity of low-dose dobutamine stress magnetic
resonance (DSMR) to detect hibernating myocardium is
superior to that of radionuclide methods (49), and endocar-
dial and epicardial border definition are superior compared
with those of echocardiography (50). Potentially sensitivity
could be improved further by the use of myocardial tagging
(Fig. 3) (51); however, this potential improvement needs to
be confirmed in a controlled, prospective investigation. A
more recent approach to hibernating myocardium is the
assessment of the thickness and function of the remaining
nonenhanced viable rim, which can potentially be combined
with the previously mentioned parameters (52,53).
Assessment of prognosis. Prognosis is progressively worse
with increasing amounts of scar (54). Some evidence has
suggested that scar detected by CMR is a stronger predictor
of adverse clinical outcome than LVEF and volumes (55).
In patients with fewer than 6 scarred segments, the
presence of scar on LGE images was more accurate for
predicting events than hibernating myocardium assessed by
low-dose DSMR. Conversely, in patients with myocardial
scar involving more than 6 segments, hibernating myocar-
dium assessed by low-dose DSMR was a better predictor of
events than scar tissue with LGE (56). Dall’Armellina et al.
(57) investigated the relative merit of high-dose DSMR in
200 patients with EF 55%. Although DSMR was an
independent predictor of outcome with EF of 40% to 55%,
it had no additional value in the presence of EF40% (57).
From a clinical perspective, a CMR examination includ-
ing scar imaging and dobutamine contractile reserve may
well emerge as the gold standard, with the particular
advantage of targeting more than one surrogate parameter
of hibernating myocardium. Its accuracy compared with
that of other available techniques to predict functional
recovery is shown in Figure 3. In general, methods looking
at functional response to stress seem to be more predictive
for functional recovery after revascularization than methods
looking at nonviability (scar) or at cellular integrity.
CMR of Ischemia
Wall motion imaging during high-dose (40 g·kg1·min1
 atropine) DSMR as well as perfusion imaging during
vasodilator stress are highly accurate for assessing ischemia
(Table 6) and are appropriate tests for certain groups with
stable angina (8,17,58,59). They are particularly helpful in
combination with LGE to determine whether there are
areas with ischemia extending beyond irreversibly scarred
myocardium (60).
DSMR mirrors DSE protocols and analyses (50). In
combination with scar imaging, this technique delivers
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dium. Quantitative assessment of strain at peak stress is
mildly more accurate for ischemia detection than visual
analysis alone (61). This may be of specific importance in
patients with ICM because LV remodeling results in
complex wall motion abnormalities at rest. High-dose
dobutamine stress is not recommended in patients with EF
25% due to increased incidence of complications (62).
In addition to being more accurate, quantitative analysis
of regional strain or the rapid untwisting of the heart in
isovolumic relaxation might allow for the detection of
ischemia below peak stress (63), potentially reducing the
need for high-dose dobutamine stress (64).
Advanced first-pass perfusion CMR imaging during
adenosine-induced coronary vasodilation has unprecedented
spatial resolution (2  2 mm or better) and may detect
schemia in thinned and remodeled segments. Examples are
hown in Figures 5 and 6. However, so far, there are no
pecific data on the accuracy of CMR perfusion imaging in
atients with heart failure and low EF. Recent published
eports have been based on patient populations with near
ormal EF (20,65) or did not look at subgroups of patients
ith different levels of LV function (66). These data may be
mportant because the relatively slow transport of the
ontrast agent might obscure inducible ischemia. Future
evelopments involve dobutamine stress perfusion imaging
67) and measurements of blood oxygenation levels (68) as
n alternative to adenosine first-pass perfusion imaging.
An additional advantage of imaging ischemia at the same
ime as hibernating myocardium is the potential detection
f inducible ischemia in a coronary artery territory other
han the territory under investigation for hibernating
Figure 6 Images of a 60-Year-Old Male Patient With RCA-CTO
CMR showed reduced LV systolic function (LVEF 25%) with severe wall motion abn
showed moderate hypokinesia. There was nontransmural scarring (25% to 50%) in
All dysfunctional segments increased wall thickening with low-dose DSMR and sho
ES  end-systolic; LAD  left anterior descending coronary artery; other abbreviatyocardium.Conclusions
Heart failure secondary to chronic CAD is a major problem
in clinical cardiology. In patients with inducible ischemia
and hibernating myocardium, revascularization is likely to
result in improvement of regional and global LV function,
heart failure symptoms, and long-term prognosis. Guide-
lines recommend revascularization in patients with hiber-
nating myocardium based on previous evidence suggesting
that patients with hibernating myocardium who were
treated medically have an adverse prognosis. However, the
STICH trial has challenged this view, particularly when
DSE or SPECT is used to define hibernating myocardium.
Noninvasive assessment of hibernating myocardium in pa-
tients with ICM can guide treatment; however, in light of
this study, we may need to reconsider the optimal approach.
Various tests are available for identifying hibernating
myocardium: SPECT imaging is sensitive for detecting
cellular integrity and is widely available. DSE is also widely
available; however, the sensitivity of this technique is infe-
rior, and the prognostic relevance of both SPECT and DSE
have been called into question by the STICH data.
In patients with severely depressed EF, PET imaging
may be useful for assessment of hibernating myocardium
because this technique has high sensitivity and superior
resolution to SPECT. Contrast-enhanced CMR in combi-
nation with low-dose dobutamine stimulation seems to be
the most accurate technique, with a growing body of
evidence to support it. At this time, we tend to restrict the
use of CMR to more complex patients. Future research will
help us to better define the relative contribution of ischemia
to outcome in patients with hibernating myocardium and
the relative value of the different diagnostic techniques,
evere Proximal LAD Disease
ties at rest predominantly in the anterior wall and the septum. The inferior wall
nterior wall, septum (1% to 25%), and inferior wall (1% to 25%; arrowheads).
iffuse inducible ischemia with adenosine (arrowheads). ED  end-diastolic;
s in Figures 3, 4, and 5.and S
ormali
the a
wed d
ions aparticularly PET and CMR.
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